The use of epoetin alfa biosimilar in the anemia management in hemodialysis patients
| Autor: | I. O. Dudar, E. K. Krasjuk, Y. I. Honchar, O. M. Loboda, I. M. Shifris, V. F. Krot, V. M. Savchuk |
|---|---|
| Jazyk: | English<br />Ukrainian |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Український Журнал Нефрології та Діалізу, Iss 3(71) (2021) |
| Druh dokumentu: | article |
| ISSN: | 2304-0238 2616-7352 |
| DOI: | 10.31450/ukrjnd.3(71).2021.05 |
| Popis: | Abstract. The present study aimed to evaluate the efficacy and safety of EMAVAIL (epoetin alfa) in the correction of anemia in hemodialysis patients. Methods. A total of 36 patients undergoing regular hemodialysis were enrolled in this prospective study. Among the patients were 19 (53%) men and 17 (47%) women with severe anemia (hemoglobin (Hb) level ≤ 90 g/L). The mean patients' age was 48.41±1.82 years, an average dialysis vintage consisted of 42.38±10.41 months. All the patients had thrice-weekly hemodialysis sessions, with a mean duration of 12.6 ± 0.51 hours per week and Kt/V 1.27 ± 0.08. All the patients were treated with biosimilar of epoetin alfa EMAVAIL intravenously three times a week in adjustable doses. The follow-up period was 56 days. Results. At the study entry, the mean Hb level in hemodialysis patients was 81.7±0,93 g/L. In 56 days of anemia treatment, the concentration of Hb increased to 109.17±1.75 g/L. Eventually, 32 (89%) patients achieved the target Hb level (110 g/L); 6 (17%) patients had adverse events (mild hypertension). There were no serious adverse events. Conclusions. EMAVAIL is an effective and safe epoetin alfa biosimilar for anemia management in hemodialysis patients. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|